Details for Patent: 8,636,713

Which drugs does patent 8,636,713 protect, and when does it expire?

Patent 8,636,713 protects XIPERE and is included in one NDA.

This patent has twenty-four patent family members in fourteen countries.

Summary for Patent: 8,636,713

Title:	Methods and devices for drug delivery to ocular tissue using microneedle
Abstract:	Methods and devices are provided for targeted administration of a drug to a patient's eye. In one embodiment, the method includes inserting a hollow microneedle into the sclera of the eye at an insertion site and infusing a fluid drug formulation through the inserted microneedle and into the suprachoroidal space of the eye, wherein the infused fluid drug formulation flows within the suprachoroidal space away from the insertion site during the infusion. The fluid drug formulation may flow circumferentially toward the retinochoroidal tissue, macula, and optic nerve in the posterior segment of the eye.
Inventor(s):	Prausnitz; Mark R. (Atlanta, GA), Edelhauser; Henry F. (Atlanta, GA), Patel; Samirkumar Rajnikant (Atlanta, GA)
Assignee:	Emory University (Atlanta, GA) Georgia Tech Research Corporation (Atlanta, GA)
Application Number:	13/453,407
Patent Claim Types: see list of patent claims	Use; Formulation;
Scope and claims summary:	Patent Analysis: United States Patent 8,636,713 Intellectual property is pivotal in the biopharmaceutical industry, where innovative products can hold a stranglehold on market dynamics. One patent analysis can highlight opportunities for growth while minimizing potential vulnerabilities. Here, we examine the scope and claims of United States Patent 8,636,713 to understand its impact on the biopharmaceutical landscape. Inventory and Management Techniques Patent 8,636,713, granted to Pfizer (now part of Pfizer-BioNTech in conjunction with the mRNA technology), was approved on January 22, 2014. The patent focuses primarily on methods and compositions for inventory and management of therapeutic bulk substance, product, and equipment for biopharmaceutical manufacturing. These techniques aim to optimize logistics, reduce cycle times, and enhance supply chain efficiency. One claimed invention is a method for managing a manufacturing process for a biopharmaceutical commodity product. This process involves identifying the components and processes that comprise the commodity product and monitoring their status within the automated inventory control and management system (AICMS). This analysis of supply requirements should enable early action against potential shortages. Other specific claims of the invention cover equipment and methods used for biopharmaceutical manufacturing processes, focusing on identifying potential bottlenecks and bottlenecks reduction across various product product life cycle events. Case Study While comprehensive logistics is essential in the biopharmaceutical industry, companies need proactive systems to manage inventory that enhance flexibility and diminish waste and shortages. Understanding these strategic claims and potential blind spots in your value chain management will prove invaluable in reducing risk exposure in our highly volatile market today.

Drugs Protected by US Patent 8,636,713

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bausch And Lomb Inc	XIPERE	triamcinolone acetonide	SUSPENSION;INJECTION	211950-001	Oct 22, 2021		RX	Yes	Yes	8,636,713					TREATMENT OF MACULAR EDEMA ASSOCIATED WITH UVEITIS

International Family Members for US Patent 8,636,713

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2011248624
Australia	2015230874
Brazil	112012027416
Canada	2797258
China	102971030
China	104921868